

Presentation No.	Presentation Title	Chair/Speaker's Name	Affiliation
FACO Poster Session 3 * This is not charing session.			
FP3-1	Cisplatin-activated PAI-1 secretion in the cancer-associated fibroblasts with paracrine effects promoting esophageal squamous cell carcinoma progression and causing chemoresistance	Yun Che	Department of Thoracic Surgery, Department of Thoracic Surgery, National Cancer Center/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, China
FP3-2	The value of 18F-FDG PET/CT in diagnosis of pretherapy esophageal squamous cell carcinoma and its correlation with expression of cyclin	Junxing Huang	Department of Oncology, Taizhou People's Hospital affiliated to Nantong University, China
FP3-3	(Withdrawn)		
FP3-4	Combined promoter methylation detection of free-circulating tumor-associated DNA in colorectal cancer	Weiwei Tang	Department of Medical Oncology, Xiamen Cancer Hospital, The First Affiliated Hospital of Xiamen University, China/Department of Oncology, Fujian Medical University, China
FP3-5	Combined detection of transforming growth factor a and insulin like growth factor II predicts efficacy of raltitrexed in treatment of elderly patients with advanced rectal cancer	Gaohua Han	Department of Oncology, Taizhou People's Hospital affiliated to Nantong University, China
FP3-6	Cost-effectiveness analysis of capecitabine plus irinotecan versus fluorouracil plus irinotecan for metastatic colorectal cancer in China	Qiuji Wu	Department of Medical Oncology, Cancer Center, West China Hospital, Sichuan University, China
FP3-7	Trends in the incidence, prevalence, and survival outcomes of appendiceal adenocarcinoma	Wenqiang Xiang	Department of Colorectal Surgery, Fudan University Shanghai Cancer Center, China/Department of Oncology, Shanghai Medical College, Fudan University, China
FP3-8	Prognosis of three histological subtypes of colorectal adenocarcinoma: A retrospective analysis of 8005 Chinese patients	Chao Li	Fudan University Shanghai Cancer Center, China
FP3-9	COX-2 expression in circulating tumor cells for prognosis prediction in patients with colorectal cancer	Jinlin Cai	The Sixth Affiliated Hospital, Department of Colorectal Surgery, Sun Yat-sen University, China
FP3-10	Reduced-ports minimally invasive surgery for sigmoid colon cancer: Comparison of three-arm robotics with two-ports laparoscopy	Sang Woo Lim	Colorectal, Surgery, Hallym University College of Medicine, Hallym University Sacred Heart Hospital, Korea
FP3-11	The value of chemotherapy in Stage II colon cancer: Much less than we thought	Jianfei Fu	Department of Colorectal Surgery, Zhejiang University Jinhua Central Hospital, China
FP3-12	Transrectal ultrasound-guided puncture combined with colonoscopic biopsy vs. colonoscopic biopsy alone in the diagnosis of protruding lesions in the mid-low rectum	Liu Min	Department of Ultrasound, Sun Yat-sen University Cancer Center, China
FP3-13	Adjuvant chemotherapy improves prognosis in resectable stage IV colorectal cancer with regional nodal metastasis: A propensity score-based analysis	Hiroaki Nozawa	Department of Surgical Oncology, The University of Tokyo, Japan
FP3-14	Clinical characteristics and prognostic factors of primary extranodal classical Hodgkin lymphoma: A retrospective study of 27 cases	Mingzi Yang	Department of Lymphoma, Key Laboratory of Carcinogenesis and Translational Research (Ministry of Education), Peking University Cancer Hospital & Institute, China
FP3-15	Clinicopathological features and prognosis of 387 cases with classical Hodgkin lymphoma from China	Mingzi Yang	Department of Lymphoma, Key Laboratory of Carcinogenesis and Translational Research (Ministry of Education), Peking University Cancer Hospital & Institute, China
FP3-16	Anemia has a negative impact on the outcome of patients with Hodgkin lymphoma	Weiping Liu	Department of Lymphoma, Key Laboratory of Carcinogenesis and Translational Research (Ministry of Education), Peking University Cancer Hospital & Institute, China
FP3-17	Hepatitis B virus infection status is not associated with poor prognosis in classical Hodgkin lymphoma patients	Weiping Liu	Department of Lymphoma, Key Laboratory of Carcinogenesis and Translational Research (Ministry of Education), Peking University Cancer Hospital & Institute, China
FP3-18	A clinical study on CD33-directed chimeric antigen receptor modified NK cells in patient with refractory or relapsed acute myeloid leukemia	Leiming Xia	Department of Hematology, The Third Affiliated Hospital of Anhui Medical University, China
FP3-19	Impact of molecular response of Nilotinib for BCR/ABL1 transcripts > 10% with Imatinib 3 and/or 6 months by Sokal risk in chronic phase chronic myelogenous leukemia	Zhijian Cao	Hematology, Harbin Institute of Hematology & Oncology, China

Presentation No.	Presentation Title	Chair/Speaker's Name	Affiliation
FP3-20	PI3K/AKT activation induce Ibrutinib resistance in chronic lymphocytic leukemia	Li Yue	Jiangsu Province Hospital, the First Affiliated Hospital of Nanjing Medical University, China/Department of Cancer Biology, Cleveland Clinic, Lerner Research Institute, USA
FP3-21	Lymphoma patients with lower CD34+ cells yields can benefit from autologous hematopoietic stem cell transplantation	Weiping Liu	Department of Lymphoma, Key Laboratory of Carcinogenesis and Translational Research (Ministry of Education), Peking University Cancer Hospital & Institute, China
FP3-22	Efficacy and safety of allogeneic stem-cell transplantation as salvage therapy for peripheral T-cell lymphomas	Ying Zhou	Oncology, Department of Oncology, Nantong Tumor Hospital, China
FP3-23	T-cell receptor signaling pathway, a novel candidate therapeutic target for the treatment of AITL.	Yalu Liu	Key Laboratory of Carcinogenesis and Translational Research (Ministry of Education), Department of Lymphoma, Peking University Cancer Hospital & Institute, China
FP3-24	Combination of enzastaurin and ibrutinib synergistically induces anti-tumor effects in diffuse large B cell lymphoma	Yizi He	Key laboratory of Carcinogenesis and Translational Research (Ministry of Education), Department of Lymphoma, Peking University Cancer Hospital & Institute, China
FP3-25	A real world study of efficacy and safety with apatinib therapy in advanced neuroendocrine carcinoma patients	Chao Chen	Department of Medical Oncology of PLA Cancer Center, Bayi Hospital Affiliated Nanjing University of Chinese Medicine, China
FP3-26	A real world study of efficacy and safety with apatinib therapy in advanced sarcoma patients	Chao Chen	Department of Medical Oncology of PLA Cancer Center, Bayi Hospital Affiliated Nanjing University of Chinese Medicine, China
FP3-27	The role of random cervical biopsies in addition to colposcopy-directed biopsies in detection of CIN2+	Nutthaporn Chandeying	Department of Obstetrics and Gynecology, Faculty of Medicine Vajira Hospital, Navamindradhiraj University, Thailand
FP3-28	Value of three-dimensional transrectal ultrasound to predict pathological complete response after preoperative chemoradiotherapy for lower rectal cancer	Liu Min	Department of Ultrasound, Sun Yat-sen University Cancer Center, China
FP3-29	YAP is essential for Treg mediated suppression of anti-tumor immunity	Xuhao Ni	The First Affiliated Hospital, Nanjing Medical University, China/Immunology and Hematopoiesis Division, Department of Oncology, Bloomberg-Kimmel Institute, Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins University School of Medicine, USA
FP3-30	A novel 4-gene prognostic signature for hypermutated colorectal cancer (CRC)	Hanguang Hu	Department of Medical Oncology, The Second Affiliated Hospital, Zhejiang University School of Medicine, China
FP3-31	Malignant rhabdoid tumor: A long time retrospective study	Wen Cai	Department of Medical Oncology, The Second Affiliated Hospital, Zhejiang University School of Medicine, China/Cancer Institute (Key Laboratory of Cancer Prevention and Intervention, China National Ministry of Education), the Second Affiliated Hospital, School of Medicine, Zhejiang University, China
FP3-32	Universal screening for Lynch Syndrome in a large consecutive cohort of Chinese colorectal cancer patients: High prevalence and unique molecular features	Wu Jiang	Department of Colorectal Surgery, Sun Yat-sen University Cancer Center, China
FP3-33	Clinicopathological features and metastatic patterns of patients with gastroenteropancreatic mixed adenoneuroendocrine carcinoma	Panpan Zhang	Department of GI, Beijing Cancer Hospital, China
FP3-34	Effect of a combined treatment with Enteral nutritional powder and megestrol acetate for malnourished cancer patients	Jun B. Duan	Medical Oncology, Sha'anxi Provincial People's Hospital, China